Induction of Peptide-specific CTL Activity and Inhibition of Tumor Growth Following Immunization with Nanoparticles Coated with Tumor Peptide-MHC-I Complexes
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Tumor peptides associated with MHC class I molecules or their synthetic variants have attracted great attention for their potential use as vaccines to induce tumor-specific CTLs. However, the outcome of clinical trials of peptide-based tumor vaccines has been disappointing. There are various reasons for this lack of success, such as difficulties in delivering the peptides specifically to professional Ag-presenting cells, short peptide half-life in vivo, and limited peptide immunogenicity. We report here a novel peptide vaccination strategy that efficiently induces peptide-specific CTLs. Nanoparticles (NPs) were fabricated from a biodegradable polymer, poly(D,L-lactic-co-glycolic acid), attached to H-2Kb molecules, and then the natural peptide epitopes associated with the H-2Kb molecules were exchanged with a model tumor peptide, SIINFEKL (OVA257-268). These NPs were efficiently phagocytosed by immature dendritic cells (DCs), inducing DC maturation and activation. In addition, the DCs that phagocytosed SIINFEKL-pulsed NPs potently activated SIINFEKL-H-2Kb complex-specific CD8+ T cells via cross-presentation of SIINFEKL. In vivo studies showed that intravenous administration of SIINFEKL-pulsed NPs effectively generated SIINFEKL-specific CD8+ T cells in both normal and tumor-bearing mice. Furthermore, intravenous administration of SIINFEKL-pulsed NPs into EG7.OVA tumor-bearing mice almost completely inhibited the tumor growth. These results demonstrate that vaccination with polymeric NPs coated with tumor peptide-MHC-I complexes is a novel strategy for efficient induction of tumor-specific CTLs.
Abstract
Tumor peptides associated with MHC class I molecules or their synthetic variants have attracted great attention for their potential use as vaccines to induce tumor-specific CTLs. However, the outcome of clinical trials of peptide-based tumor vaccines has been disappointing. There are various reasons for this lack of success, such as difficulties in delivering the peptides specifically to professional Ag-presenting cells, short peptide half-life in vivo, and limited peptide immunogenicity. We report here a novel peptide vaccination strategy that efficiently induces peptide-specific CTLs. Nanoparticles (NPs) were fabricated from a biodegradable polymer, poly(D,L-lactic-co-glycolic acid), attached to H-2Kb molecules, and then the natural peptide epitopes associated with the H-2Kb molecules were exchanged with a model tumor peptide, SIINFEKL (OVA257-268). These NPs were efficiently phagocytosed by immature dendritic cells (DCs), inducing DC maturation and activation. In addition, the DCs that phagocytosed SIINFEKL-pulsed NPs potently activated SIINFEKL-H-2Kb complex-specific CD8+ T cells via cross-presentation of SIINFEKL. In vivo studies showed that intravenous administration of SIINFEKL-pulsed NPs effectively generated SIINFEKL-specific CD8+ T cells in both normal and tumor-bearing mice. Furthermore, intravenous administration of SIINFEKL-pulsed NPs into EG7.OVA tumor-bearing mice almost completely inhibited the tumor growth. These results demonstrate that vaccination with polymeric NPs coated with tumor peptide-MHC-I complexes is a novel strategy for efficient induction of tumor-specific CTLs.
참고문헌 (39)
- Durgeau A, "Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy", Front Immunol, 9, pp.14~ (2018)
- Malonis RJ, "Peptide-based vaccines : current progress and future challenges", Chem Rev, 120, pp.3210~3229 (2020)
- Wagner S, "Colorectal cancer vaccines : Tumor-associated antigens vs neoantigens", World J Gastroenterol, 24, pp.5418~5432 (2018)
- Tanna JG, "Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cells", Cytotherapy, 21, pp.278~288 (2019)
- Schietinger A, "Specificity in cancer immunotherapy", Semin Immunol, 20, pp.276~285 (2008)
- Minati R, "A roadmap toward the definition of actionable tumor-specific antigens", Front Immunol, 11, pp.583287~ (2020)
- Olsen LR, "Bioinformatics for cancer immunotherapy target discovery", Cancer Immunol Immunother, 63, pp.1235~1249 (2014)
- Pallerla S, "Cancer vaccines, treatment of the future : With emphasis on her2-positive breast cancer", Int J Mol Sci, 22, pp.22~ (2021)
- Cho HI, "BiVax : a peptide", poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses, 2013, pp.62, 787~799
- Barrios K, "TriVax-HPV : an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers", Cancer Immunol Immunother, 61, pp.1307~1317 (2012)
- Kumai T, "Peptide vaccines in cancer-old concept revisited", Curr Opin Immunol, 45, pp.1~7 (2017)
- Kumai T, "Cancer immunotherapy : moving forward with peptide T cell vaccines", Curr Opin Immunol, 47, pp.57~63 (2017)
- Ahonen CL, "Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN", J Exp Med, 199, pp.775~784 (2004)
- He X, "Peptide delivery systems for cancer vaccines", Adv Ther, 1, pp.1800060~ (2018)
- Khong H, "Adjuvants for peptide-based cancer vaccines", J Immunother Cancer, 4, pp.56~ (2016)
- Xia F, "TCR and CD28 concomitant stimulation elicits a distinctive calcium response in naive T cells", Front Immunol, 9, pp.2864~ (2018)
- Davis SJ, "The nature of molecular recognition by T cells", Nat Immunol, 4, pp.217~224 (2003)
- Raskov H, "Cytotoxic CD8+ T cells in cancer and cancer immunotherapy", Br J Cancer, 124, pp.359~367 (2021)
- Seongju Jeong, "Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy", Immune Network, 20(1), pp.1~20 (2020), 대한면역학회[DOI]
- Se Jin Im, "Re-defining T-Cell Exhaustion: Subset, Function, and Regulation", Immune Network, 20(1), pp.1~19 (2020), 대한면역학회[DOI]
- 정호현, "Polymeric Nanoparticles Containing Both Antigen and Vitamin D3 Induce Antigen-Specific Immune Suppression", Immune Network, 19(3), pp.1~12 (2019), 대한면역학회
- Lee YH, "Baccatin III, a synthetic precursor of taxol, enhances MHC-restricted antigen presentation in dendritic cells", Int Immunopharmacol, 11, pp.985~991 (2011)
- Oyewumi MO, "Nano-microparticles as immune adjuvants : correlating particle sizes and the resultant immune responses", Expert Rev Vaccines, 9, pp.1095~1107 (2010)
- Sadat SM, "Effects of size and surface charge of polymeric nanoparticles on in vitro and in vivo applications", J Biomater Nanobiotechnol, 7, pp.91~108 (2016)
- Lou D, "Antibody-oriented strategy and mechanism for the preparation of fluorescent nanoprobes for fast and sensitive immunodetection", Langmuir, 35, pp.4860~4867 (2019)
- Slingluff CL Jr, "The present and future of peptide vaccines for cancer : single or multiple, long or short, alone or in combination", Cancer J, 17, pp.343~350 (2011)
- Dellacherie MO, "Covalent conjugation of peptide antigen to mesoporous silica rods to enhance cellular responses", Bioconjug Chem, 29, pp.733~741 (2018)
- Foged C, "Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model", Int J Pharm, 298, pp.315~322 (2005)
- Kurts C, "Cross-priming in health and disease", Nat Rev Immunol, 10, pp.403~414 (2010)
- Chen L, "Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity", Front Immunol, 4, pp.388~ (2013)
- Schiavoni G, "Type I interferons as stimulators of DC-mediated cross-priming : impact on anti-tumor response", Front Immunol, 4, pp.483~ (2013)
- Rundqvist H, "Cytotoxic T-cells mediate exercise-induced reductions in tumor growth", eLife, 9, pp.9~ (2020)
- Gong Y, "Tumor-infiltrating CD62L+PD-1-CD8 T cells retain proliferative potential via Bcl6 expression and replenish effector T cells within the tumor", PLoS One, 15, pp.e0237646~ (2020)
- Huang AY, "Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens", Science, 264, pp.961~965 (1994)
- Arina A, "Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming", Exp Hematol, 30, pp.1355~1364 (2002)
- Wang Q, "Injectable PLGA based colloidal gels for zero-order dexamethasone release in cranial defects", Biomaterials, 31, pp.4980~4986 (2010)
- Hamdy S, "Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations", Adv Drug Deliv Rev, 63, pp.943~955 (2011)
- Keegan ME, "In vitro evaluation of biodegradable microspheres with surface-bound ligands", J Control Release, 110, pp.574~580 (2006)
- Cao J, "Development of PLGA micro-and nanorods with high capacity of surface ligand conjugation for enhanced targeted delivery", Asian J Pharm Sci, 14, pp.86~94 (2019)